Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors

INTRODUCTION: In the randomized, open-label, parallel-arm, active-controlled phase III AWARD-CHN2 trial, once-weekly dulaglutide plus concomitant oral antihyperglycemic medications (OAMs) improved HbA1c over 26 weeks compared with once-daily insulin glargine in patients with type 2 diabetes mellitus...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yan, Zhu, Jiankun, Wu, Haiya, Deng, Yuying, Ji, Qiuhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479006/
https://www.ncbi.nlm.nih.gov/pubmed/34453682
http://dx.doi.org/10.1007/s13300-021-01139-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479006/
https://www.ncbi.nlm.nih.gov/pubmed/34453682
http://dx.doi.org/10.1007/s13300-021-01139-2

Ejemplares similares